RFS

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Friday, March 29, 2024
PDAC, Completeness, Patient, Neoplasm, DNA, RFS, Therapy, Cancer, Pharmaceutical industry

BOSTON, March 29, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2023, and provided recent business highlights.

Key Points: 
  • BOSTON, March 29, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2023, and provided recent business highlights.
  • The independent data monitoring committee completed the safety review of ELI-002 7P Phase 1 trial patients and confirmed the recommended Phase 2 trial dose.
  • No safety concerns were identified, and no dose limiting toxicities and no ≥ grade 3 treatment related adverse events were observed.
  • Cash and cash equivalents as of December 31, 2023, were $12.9 million, compared to $6.2 million as of December 31, 2022.

Automated Bus Consortium issues new request for solutions (RFS) to procure highly automated transit buses

Retrieved on: 
Wednesday, April 3, 2024
Construction & Property, Natural Resources, Defense, Environment, Engineering, Trucking, Urban Planning, Rail, Maritime, Logistics, Supply Chain Management, Landscape, Air, Manufacturing, Transport, Architecture, Other Energy, Utilities, Oil, Gas, Coal, Contracts, Alternative Energy, Energy, Public Transport, Sustainability, Building Systems, Mining, Minerals, Nuclear, Automation, ABC, RFS, Trinity Metro, RATP Group, Dallas Area Rapid Transit, Capital Area Transportation Authority, Consortium, Michigan State University, NJ TRANSIT, Metropolitan Transit Authority, AECOM, Public Transport Corporation, Rail transport

The Automated Bus Consortium™, a collective of U.S. transit agencies and several state departments of transportation, has released a new request for solutions (RFS) to procure heavy-duty highly automated transit buses.

Key Points: 
  • The Automated Bus Consortium™, a collective of U.S. transit agencies and several state departments of transportation, has released a new request for solutions (RFS) to procure heavy-duty highly automated transit buses.
  • “We have made great strides in further advancing the automated transit industry through our previous request for solutions,” said Jean Ruestman, administrator of the Office of Passenger Transportation at the Michigan Department of Transportation.
  • Pilot routes for these vehicles would include rural and urban deployments, bus rapid transit, bus yard and local bus service.
  • Formed by AECOM, the Automated Bus Consortium is a first-of-its-kind approach to cooperatively investigate the feasibility of automated bus projects and accelerate the deployment of automated transit technologies.

The Dismantling of the American Timber Industry: American Loggers Council Warns of Consequences

Retrieved on: 
Monday, March 25, 2024
Shift, Wood, Carbon, Boise Cascade, Bioproduct, Georgia-Pacific, Paperboard, Legislation, Clearwater Paper, Aviation biofuel, Congress, RFS, Economic development, Policy, Cutback, Renewable energy, Biomass, Electricity, Roseburg Forest Products, Climate change, Graphic Packaging, Disease, News, Essity, WestRock, Health, Natural gas, Pactiv Evergreen, Environment, Steel, International Paper, EPA, Hydrogen, World Bank, Administration, Government, Medicine

WASHINGTON, March 25, 2024 /PRNewswire-PRWeb/ -- It seems like every time a forest product mill or plant shuts down (monthly if not weekly) it's viewed as a singular isolated incident. But viewed collectively, the cumulative impacts and magnitude become more focused and apparent. The individual incidents are all symptoms of a larger serious condition that diagnosed properly reveals and represents an unhealthy state of the U.S. timber and forest products industries.

Key Points: 
  • Many contributing factors leading to the decline of the U.S. timber and forest products industries are government policy, regulations, restrictions, unfair trade practices, federal timber supply constraints, and incessant litigation.
  • While there has been some new mill construction and expansion, this cannot be assumed to be an equal offset.
  • According to the World Bank, the U.S. imports over $40 billion in wood products from Canada, China and Brazil.
  • Note: Prolonged mill quotas (timber delivery supply limits and restrictions) have been imposed by some southeastern mills reducing volume to levels unable sustain cashflow/debt service for loggers.

LPL Financial Welcomes RFS Financial Services

Retrieved on: 
Monday, March 4, 2024
SAN, Professional, Investment, RIA, RFS, Business development, LPL, OSJ, Partnership

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- LPL Financial LLC announced today that RFS Financial Securities has joined LPL Financial’s broker-dealer, RIA and custodial platforms.

Key Points: 
  • SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- LPL Financial LLC announced today that RFS Financial Securities has joined LPL Financial’s broker-dealer, RIA and custodial platforms.
  • The team reported serving approximately $140 million in advisory, brokerage and retirement plan assets* and joins LPL from Lincoln Financial Advisors.
  • LPL strives to be a committed partner to our financial advisors, offering a wide range of differentiated services and innovative technology experiences so they can run their practice as they see fit.
  • We look forward to a long-lasting partnership with the entire team at RFS Financial Services.”

CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Tuesday, February 27, 2024
FACS, PFS, Recurrence, BCG, Medical director, RFS, TURBT, Bladder cancer, Cancer, Patient, Disease, Face, Pharmaceutical industry

IRVINE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the first patient has been dosed in the PIVOT-006 Phase 3 clinical trial of cretostimogene for the treatment of patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Key Points: 
  • “The dosing of the first patient in our PIVOT-006 trial advances cretostimogene earlier in the treatment paradigm for NMIBC patients who face limited treatment options, frequent disease recurrence and repetitive surgery,” said Arthur Kuan, Chairman and Chief Executive Officer, CG Oncology.
  • The initial induction course is six weekly doses of cretostimogene containing 1x1012 VPs per milliliter.
  • The primary endpoint of this trial is overall RFS, with secondary endpoints including RFS at 12 and 24 months and PFS.
  • Cretostimogene is a novel therapy which has the potential to be a paradigm shift in how we might manage the ongoing burden of this highly recurrent aspect of bladder cancer.”

CVR Energy Reports Fourth Quarter and Full-Year 2023 Results and Announces a Cash Dividend of 50 Cents Per Share

Retrieved on: 
Tuesday, February 20, 2024
Ammonia, RFS, Overalls, Sale, Debt-to-GDP ratio, Conference, CVR Partners, CVI, Rest, Webcast, UAN, Energy, Lamp, CVR, Partner

Declared quarterly cash dividend of 50 cents for the fourth quarter 2023, bringing the cumulative cash dividends declared for 2023 to $4.50 per share.

Key Points: 
  • Declared quarterly cash dividend of 50 cents for the fourth quarter 2023, bringing the cumulative cash dividends declared for 2023 to $4.50 per share.
  • Fourth quarter 2023 EBITDA was $204 million, compared to fourth quarter 2022 EBITDA of $313 million.
  • Adjusted EBITDA for the fourth quarter of 2023 was $170 million, compared to adjusted EBITDA of $388 million in the fourth quarter of 2022.
  • CVR Energy announced a fourth quarter 2023 cash dividend of 50 cents per share.

MDWerks Highlights the Environmental Sustainability Advantages of its Energy Wave Technology Solutions in the Alcoholic Beverages and Industrial Sectors

Retrieved on: 
Thursday, March 7, 2024
Wine & Spirits, Technology, Forest Products, Food, Beverage, Agriculture, Natural Resources, Retail, Agritech, Environment, Food Tech, Sustainability, Tree, OTC, RFS, Ageing, Wood, Bed, Carbon, Seedling, Renewable energy

Steven Laker, CEO of MDWerks, commented, “As companies increasingly look to reduce their carbon footprints and enhance efficiency, MDWerks is well positioned to disrupt both the alcoholic beverages and industrial sectors with its sustainable energy wave technology.

Key Points: 
  • Steven Laker, CEO of MDWerks, commented, “As companies increasingly look to reduce their carbon footprints and enhance efficiency, MDWerks is well positioned to disrupt both the alcoholic beverages and industrial sectors with its sustainable energy wave technology.
  • Key benefits of Sustainably Matured™ technology:
    RFS utilizes proprietary energy wave technology alongside its patented and proprietary molecular targeting technology to provide sustainable manufacturing solutions to industrial customers in the engineered wood, structural wood, and adhesives space.
  • Utilizing its energy wave expertise, RFS designs and builds custom manufacturing equipment that enables more efficient production lines, thereby driving greater environmental sustainability.
  • If you would like to learn more about how our solutions can improve your company’s environmental sustainability and add value to your business, please contact us on our website at https://www.rfspecialtiesus.com/contact/ .

Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

Retrieved on: 
Monday, February 26, 2024
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Recurrence, RFS, Hospital, Metastasis, IB, MSS, Risk, Prognosis, Death, Patient, Survival, Disease, Mortality, Melanoma, Medical imaging

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in Cancers 1 demonstrating that DecisionDx-Melanoma provided significantly better risk stratification than American Joint Committee on Cancer 8th Edition (AJCC8) staging in patients with stage I cutaneous melanoma (CM).

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in Cancers 1 demonstrating that DecisionDx-Melanoma provided significantly better risk stratification than American Joint Committee on Cancer 8th Edition (AJCC8) staging in patients with stage I cutaneous melanoma (CM).
  • Stage I CM tumors are considered low risk; however, since stage I encompasses a large group of patients diagnosed, many melanoma-specific deaths are seen in patients initially diagnosed with stage I disease.
  • Thus, there is a clinical gap in the low-risk treatment pathway for stage I patients.
  • The new study in Cancers provides further information that DecisionDx-Melanoma testing could enable more precise risk stratification in stage I melanomas than provided by traditional staging to better inform risk-appropriate clinical management.

Pembina Pipeline Corporation Reports Record Results for the Fourth Quarter 2023, Provides Business Update, and Declares Quarterly Common Share Dividend

Retrieved on: 
Thursday, February 22, 2024
Energy, Other Energy, Utilities, Oil, Gas, Transfer, Momentum, Carbon, Engineering, Conversation, Weather, ACG, Web browser, RFS, TC Energy, Growth, Montney, British Columbia, LNG Canada, Pipeline, WCSB, Sale, E6, Season, Tax, EPC, Corporation, Peace, Emperor, Marketing, Black & Veatch, Management, Propane, Transport, Phase, Depreciation, Partnership, Hart–Scott–Rodino Antitrust Improvements Act, BBB, Natural gas, Alliance Pipeline, Elk, Black, FID, Dow, Insurance, Hydrocarbon, Acquisition, Wildfire, Mountain Valley Pipeline, Ethane, NEBC, Ruby, NGL, Coastal GasLink Pipeline, Facility, Younger, PGI

Pembina reported record quarterly adjusted EBITDA of $1,033 million in the fourth quarter and record full year adjusted EBITDA of $3,824 million.

Key Points: 
  • Pembina reported record quarterly adjusted EBITDA of $1,033 million in the fourth quarter and record full year adjusted EBITDA of $3,824 million.
  • Results were impacted by higher incentive costs driven by Pembina's share price performance and increased shared service revenue.
  • On a per share (basic) basis, cash flow from operating activities was $1.60 per share for the fourth quarter and $4.79 per share for the full year.
  • ET) for interested investors, analysts, brokers and media representatives to discuss results for the fourth quarter of 2023.

Orca Bio Presents Promising Data on Orca-T in Two Oral Presentations at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Retrieved on: 
Friday, February 23, 2024
Research, Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, MAC, AML, Syndrome, MD, Assistant, Physician, RFS, NRM, MMF, Weill Cornell Medicine, Risk, Thiotepa, Graft-versus-host disease, Bone marrow, Society, BFT, MDS, CNI, Patient, Hematopoietic stem cell transplantation, NewYork-Presbyterian Hospital, Survival, Transplant, Acute myeloid leukemia, Weill Cornell Medical Center, Cancer, Busulfan, Pharmaceutical industry

In the first of two oral presentations, findings from a retrospective analysis compared historical outcomes between Orca-T and a standard of care allogeneic stem cell transplant (alloHSCT) plus post-transplant cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis in patients with hematologic malignancies receiving myeloablative conditioning (MAC).

Key Points: 
  • In the first of two oral presentations, findings from a retrospective analysis compared historical outcomes between Orca-T and a standard of care allogeneic stem cell transplant (alloHSCT) plus post-transplant cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis in patients with hematologic malignancies receiving myeloablative conditioning (MAC).
  • Within the non-randomized cohorts of varying conditioning regimens and disease types, Orca-T demonstrated favorable results across clinical outcomes including relapse-free survival (RFS), non-relapse mortality (NRM) and overall survival (OS).
  • The analysis included patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) who had a median follow-up time of 15 months and 12 months in the Orca-T and PTCy cohorts, respectively.
  • The outcomes at 12 months are summarized in the table below: